From Tuesday's closing valuation, MYNZ is displaying a ton of potential upside to this $25 target.
In fact, that's over 200+% potential upside.
Now, I'm not saying this profile is going to surge to $25 this week, but over the past 52-week period it has a high of $30.
Even a partial return to those levels would mean a major move from MYNZ from current trading areas.
No. 3 MYNZ Potential Catalyst - This 2X Past Champ Oozes With Bounce/Reversal Potential
As of 12:00PM EST Tuesday, Barchart was reporting this profile to have several oversold leaning technicals.
These technicals could be signaling a healthy reversal in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Now, here are some key technicals (as of 12:00PM EST Tuesday) that could signal KULR to be leaning oversold and on the verge of a potential reversal.
- 9-Day Relative Strength Index: 26.68%
- 14-Day Relative Strength Index: 31.00%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
Keep an eye on these technicals closely.
No. 4 MYNZ Potential Catalyst - Key Company Highlights Provide A Bullish Future Outlook
Mainz Biomed Reports First Half 2022 Fi-nan-cial Results
- 127% year-over-year increase in ColoAlert revenue
- Mid-year cash balance of $26Mn
BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today financial results for the first half of the fiscal year ended June 30, 2022.
Key Corporate & Product Development Highlights
- Accelerated international commercial activities for ColoAlert, the Company’s highly efficacious and easy-to-use detection test for colorectal cancer (CRC)
- Appointed Darin Leigh, former Abbott and Luminex executive, as Chief Commercial Officer
- Established partnership with Dante Labs to market ColoAlert in Italy and the United Arab Emirates
- Initiated and enrolled the first patient in an international clinical study (ColoFuture) evaluating the integration of novel mRNA biomarkers into ColoAlert – potentially upgrading its technical profile to achieve “gold standard” status for CRC at-home testing
- Received supportive feedback from the U.S. Food and Drug Administration (FDA) on ColoAlert’s pre-submission package for its U.S. pivotal clinical trial set to commence in Q4 2022
- Achieved multiple preclinical milestones supporting the continued development of PancAlert, a potential first-in-class screening test for pancreatic cancer
- Executed a $25.8Mn (gross) public follow-on offering
- Expanded Strategic Advisory Board of global leaders in molecular diagnostic development and commercialization
“At the outset of 2022, we established ambitious commercial and product development objectives for the year, mostly around our flagship product ColoAlert. I’m pleased to report that we achieved all of our corporate growth goals for the first half period,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “The Company is fi-nan-cially well positioned to maintain momentum as ColoAlert continues to gain impressive commercial traction across Europe and select international territories, and as we ramp up to launch its U.S. pivotal clinical trial by the end of the year.”
Read the full article here.
No. 5 MYNZ Potential Catalyst - Commercial Availability of ColoAlert Grows
Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates
– ColoAlert to be marketed through Dante’s extensive database and sold via its region-specific, ecommerce websites –
BERKELEY, Calif. and MAINZ, Germany and NEW YORK, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz'' or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, and Dante Genomics, a global leader in genomics and precision medicine, announced today the formal commencement of ColoAlert’s consumer commercial program in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz’s flagship product, a highly efficacious and easy to use, at-home detection test for colorectal cancer (CRC) currently being commercialized across Europe and select international markets. With the ColoAlert test CE-IVD certified and patient collection kit CE marked to the latest IVDR requirements, ColoAlert will now be marketed through Dante’s extensive database and sold via Dante’s, region-specific, ecommerce websites.
“This is an important milestone for the company as it expands our global footprint while providing access to those who can benefit from our cutting-edge early detection CRC test in these additional major international territories,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Dante has been an exceptional partner, and we look forward to continue working closely with them as they actively market and sell ColoAlert and also as they transition from processing samples at Mainz’s in-house facility, to their own wholly-owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) where they’ll offer localized service and support.”
Dante Genomics is a global leader in whole genome sequencing and holds an existing database of tens of thousands of whole genomes. The company has a product development and commercial franchise focused on providing personalized preventive healthcare solutions. It achieves this by leveraging its robust databases and proprietary software platform to offer next-generation diagnostic tools direct to consumers and healthcare professionals.
“From our perspective, ColoAlert represents the first true step toward personalized medicine in colorectal cancer, and we are excited to leverage our expertise in genomic data to partner with Mainz in commercializing this important diagnostic tool,” said Andrea Riposati, Chief Executive Officer of Dante Genomics. “Through our partnership with Mainz, we will drive more informed healthcare decisions and empower patients with their genomic data.”
Read the full article here.
MYNZ Recap - 5 Must-Know Potential Catalyst For This Nasdaq Past Champ
No. 1 - Low Float Volatility Could Be On Display Daily
No. 2 - An H.C. Wainwright $25 Price Target
No. 3 - This 2X Past Champ Oozes With Bounce/Reversal Potential
No. 4 - Key Company Highlights Provide A Bullish Future Outlook
No. 5 - Commercial Availability of ColoAlert Grows
Coverage is officially reinitiated on MYNZ. When time permits, do this: